Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 220

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 220
---
|:--|-----------:|
| Balance at December 31, 2021 |   | $ | 25,293,149 |
| Amortization expense         | ​ | ​ | -5,588,665 |
| Intangible Impairment        | ​ | ​ | -7,460,000 |
| Balance at December 31, 2022 | ​ | ​ | 12,244,484 |
| Amortization expense         | ​ | ​ | -3,272,747 |
| Balance at December 31, 2023 | ​ | $ |  8,971,737 |

The future annual amortization related to the Company’s intangible assets is as follows as of December 31, 2023:

| ​          | ​ | ​ |         ​ |
|:-----------|:--|:--|----------:|
| 2024       |   | $ | 2,800,623 |
| 2025       | ​ | ​ | 1,754,329 |
| 2026       | ​ | ​ | 1,442,186 |
| 2027       | ​ | ​ | 1,212,871 |
| 2028       | ​ | ​ |   996,637 |
| Thereafter |   | ​ |   765,091 |
| Total      | ​ | $ | 8,971,737 |

The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years, 12 years, and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2023, are $4.9 million, $3.2 million and $0.9 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2022, are $7.2 million, $4.0 million and $1.1 million, respectively. During the year ended December 31, 2023, no impairment was recorded. During the year ended December

F-17

31, 2022, the Company determined that the intangible asset related to the Stendra® product was impaired resulting in an impairment charge of approximately $7.5 million. 7) Accrued Expenses